Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Bockisch

Showing results (41-50 of 181) with videos related to

Pageof 19
Sort By:
Radiologic Clinics of North America|August 21, 2007
PET versus PET/CT dual-modality imaging in evaluation of lung cancerLutz S Freudenberg, Sandra J Rosenbaum, Thomas Beyer, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 23, 2004
To enhance or not to enhance? 18F-FDG and CT contrast agents in dual-modality 18F-FDG PET/CTGerald Antoch, Lutz S Freudenberg, Thomas Beyer, et al.
Zeitschrift Fur Psychosomatische Medizin Und Psychotherapie|February 22, 2007
[Protective factors for anxiety and depression in thyroid cancer patients]Sefik Tagay, Wolfgang Senf, Nicole Schöpper, et al.
Nuclear Medicine Communications|March 6, 2009
Water-equivalent oral contrast agents in dual-modality PET/computed tomography scanning: does a little barium make the difference?Sonja Kinner, Patrick Veit-Haibach, Thomas C Lauenstein, et al.
The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR), [And] Section of the Society Of|July 13, 2019
The role of 124I PET/CT lesion dosimetry in differentiated thyroid cancerManuel Weber, Ina Binse, James Nagarajah, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 12, 2012
Oncologic PET/MRI, part 2: bone tumors, soft-tissue tumors, melanoma, and lymphomaChristian Buchbender, Till A Heusner, Thomas C Lauenstein, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 15, 2012
Oncologic PET/MRI, part 1: tumors of the brain, head and neck, chest, abdomen, and pelvisChristian Buchbender, Till A Heusner, Thomas C Lauenstein, et al.
Clinical Nuclear Medicine|February 8, 2012
Effects of rosiglitazone on radioiodine negative and progressive differentiated thyroid carcinoma as assessed by ¹²⁴I PET/CT imagingSandra Julia Rosenbaum-Krumme, Lutz Stefan Freudenberg, Walter Jentzen, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 13, 2011
Clinical applications of 124I-PET/CT in patients with differentiated thyroid cancerLutz S Freudenberg, Walter Jentzen, Alexander Stahl, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 14, 2010
Pre-therapeutic (124)I PET(/CT) dosimetry confirms low average absorbed doses per administered (131)I activity to the salivary glands in radioiodine therapy of differentiated thyroid cancerWalter Jentzen, Robert F Hobbs, Alexander Stahl, et al.
Pageof 19

Showing results (41-50 of 181) with videos related to

Sort By:
Pageof 19
Radiologic Clinics of North America|August 21, 2007
PET versus PET/CT dual-modality imaging in evaluation of lung cancerLutz S Freudenberg, Sandra J Rosenbaum, Thomas Beyer, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 23, 2004
To enhance or not to enhance? 18F-FDG and CT contrast agents in dual-modality 18F-FDG PET/CTGerald Antoch, Lutz S Freudenberg, Thomas Beyer, et al.
Zeitschrift Fur Psychosomatische Medizin Und Psychotherapie|February 22, 2007
[Protective factors for anxiety and depression in thyroid cancer patients]Sefik Tagay, Wolfgang Senf, Nicole Schöpper, et al.
Nuclear Medicine Communications|March 6, 2009
Water-equivalent oral contrast agents in dual-modality PET/computed tomography scanning: does a little barium make the difference?Sonja Kinner, Patrick Veit-Haibach, Thomas C Lauenstein, et al.
The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR), [And] Section of the Society Of|July 13, 2019
The role of 124I PET/CT lesion dosimetry in differentiated thyroid cancerManuel Weber, Ina Binse, James Nagarajah, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 12, 2012
Oncologic PET/MRI, part 2: bone tumors, soft-tissue tumors, melanoma, and lymphomaChristian Buchbender, Till A Heusner, Thomas C Lauenstein, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 15, 2012
Oncologic PET/MRI, part 1: tumors of the brain, head and neck, chest, abdomen, and pelvisChristian Buchbender, Till A Heusner, Thomas C Lauenstein, et al.
Clinical Nuclear Medicine|February 8, 2012
Effects of rosiglitazone on radioiodine negative and progressive differentiated thyroid carcinoma as assessed by ¹²⁴I PET/CT imagingSandra Julia Rosenbaum-Krumme, Lutz Stefan Freudenberg, Walter Jentzen, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 13, 2011
Clinical applications of 124I-PET/CT in patients with differentiated thyroid cancerLutz S Freudenberg, Walter Jentzen, Alexander Stahl, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 14, 2010
Pre-therapeutic (124)I PET(/CT) dosimetry confirms low average absorbed doses per administered (131)I activity to the salivary glands in radioiodine therapy of differentiated thyroid cancerWalter Jentzen, Robert F Hobbs, Alexander Stahl, et al.
Pageof 19